Imperial College London
Alternate

ProfessorTriciaTan

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Chair in Metabolic Medicine and Endocrinology
 
 
 
//

Contact

 

+44 (0)20 3313 8038t.tan

 
 
//

Location

 

6N6ECommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Hope:2021:10.3389/fendo.2021.735019,
author = {Hope, D and Tan, T and vincent, M},
doi = {10.3389/fendo.2021.735019},
journal = {Frontiers in Endocrinology},
pages = {1--11},
title = {Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity},
url = {http://dx.doi.org/10.3389/fendo.2021.735019},
volume = {12},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Obesity and Type 2 diabetes represent global health challenges, and there is an unmet need for long-lasting and effective pharmacotherapies. Although long-acting glucagon-like peptide-1 (GLP-1) analogues are now in routine use for diabetes and are now being utilised for obesity per se, the need for ever better treatments has driven the development of co-agonists, with the theoretical advantages of improved efficacy by targeting multiple pathways and reduced adverse effects. In this review, we highlight the past and present progress in our understanding and development of treatments based on GLP-1/glucagon co-agonism. We also reflect on the divergent effects of varying the GLP-1:glucagon activity and ratio in the context of pre-clinical and human clinical trial findings. In particular, the multiple metabolic actions of glucagon highlight the importance of understanding the contributions of individual hormone action to inform the safe, effective and tailored use of GLP-1/glucagon co-agonists to target weight loss and metabolic disease in the future.
AU  - Hope,D
AU  - Tan,T
AU  - vincent,M
DO  - 10.3389/fendo.2021.735019
EP  - 11
PY  - 2021///
SN  - 1664-2392
SP  - 1
TI  - Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
T2  - Frontiers in Endocrinology
UR  - http://dx.doi.org/10.3389/fendo.2021.735019
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2021.735019/full
UR  - http://hdl.handle.net/10044/1/91286
VL  - 12
ER  -
Download